Publications by authors named "Tiberghien P"

Arboviral diseases are a growing global health concern. Pre-existing autoantibodies (auto-Abs) neutralizing type I interferons (IFNs) can underlie encephalitis due to West Nile virus (WNV) (∼40% of patients) and tick-borne encephalitis (TBE, due to TBE virus [TBEV]) (∼10%). We report here that these auto-Abs can also underlie severe forms of rarer arboviral infections.

View Article and Find Full Text PDF
Article Synopsis
  • Prevention of ABO-incompatible red cell transfusions (ABO-it) relies on precise identification of donors and patients, with different practices in France, Germany, and the UK.
  • A study analyzed ABO-it incidents from 2013 to 2022 and found similar average frequencies of ABO-it in France (0.19) and the UK (0.28), but a higher rate in Germany (0.71), despite similar safety measures.
  • The main causes of ABO-it were errors in patient identification and administering the wrong red cell unit, highlighting the need for improved identification systems and processes to enhance transfusion safety.
View Article and Find Full Text PDF
Article Synopsis
  • Rituximab (RTX) is a key treatment for various autoimmune and chronic inflammatory diseases but increases the risk of severe infections and lowers vaccine effectiveness due to its impact on B cell responses.
  • During the COVID-19 pandemic, RTX-treated patients faced heightened disease severity, which led to delays or avoidance of RTX treatments to protect against SARS-CoV-2 infections.
  • A study of thirteen patients showed that while some had positive T cell responses post-vaccination, those recently treated with RTX had significantly lower antibody responses, suggesting a need for caution in timing vaccinations relative to RTX infusions to optimize immune protection.
View Article and Find Full Text PDF

Introduction: When Coronavirus Disease-19 (COVID-19) struck the world in December 2019, initiatives started to investigate the efficacy of convalescent plasma, a readily available source of passive antibodies, collected from recovered patients as a therapeutic option. This was based on historical observational data from previous virus outbreaks.

Methods: A scoping review was conducted on the efficacy and safety of convalescent plasma and hyperimmune immunoglobulins for COVID-19 treatment.

View Article and Find Full Text PDF

Most plasma used for manufacturing plasma-derived medicinal products (PDMPs) such as albumin, immunoglobulin (Ig), and clotting factors is obtained from source plasma collected via plasmapheresis, the majority of which is contributed by the United States (US). While the demand for PDMPs continues to rise, it remains unclear whether high-frequency plasmapheresis, such as the twice-weekly plasma donation allowed in the US, may have any (long-term) adverse health effects on the donor. To investigate the frequency at which plasma can be donated without harm to the donor, the current systematic review explores the impact of plasma donation frequency on cardiovascular health, protein depletion, and adverse events in healthy plasma donors.

View Article and Find Full Text PDF

Background And Objectives: Blood establishments strive to ensure the safety and comfort of blood donors while minimizing adverse events. This review aims to assess the efficacy and effectiveness of eating and/or drinking interventions before, during and/or after blood donation in reducing vasovagal reactions (VVRs).

Materials And Methods: We analysed randomized and non-randomized controlled trials comparing eating and/or drinking interventions to no intervention, placebo or usual practice on (pre-)syncopal VVRs and related symptoms.

View Article and Find Full Text PDF

Background And Objectives: In 2016, France allowed men who have sex with men (MSM) to donate blood if they had not had sex with men in the previous 12 months. In April 2020, this restriction was relaxed to 4 months due to the lack of negative impact observed on blood safety. This study assesses the impact of reducing this deferral period on epidemiological surveillance indicators.

View Article and Find Full Text PDF
Article Synopsis
  • Syphilis cases among blood donors in France have been rising, with a significant uptick observed in 2022 compared to earlier years.
  • Data from over 45 million donations (2007-2022) revealed that the infection rate was notably higher in males, particularly among men who have sex with men (MSM), whose risk factor percentage increased over time.
  • A non-treponemic test (NTT) was used to assess infection recency, but the data were insufficient to reliably differentiate between recent and past infections among the syphilis-positive donors.
View Article and Find Full Text PDF
Article Synopsis
  • Some countries are changing their rules about blood donation because they believe the risk of a disease called variant Creutzfeldt-Jakob disease (vCJD) has decreased since it was a big concern in the past, especially in the UK.
  • Experts held a meeting to talk about how to learn more about the disease and how to keep people safe during blood transfusions.
  • They agreed that the risk of getting vCJD from blood donors who traveled or received blood in the UK is very low now, and it's important for experts in Europe to work together to create safer guidelines for blood donation.
View Article and Find Full Text PDF

Background: Immunoglobulin (IG) therapy is widely used to treat primary and secondary immune deficiencies and as immunomodulatory agent for various disorders. There is great concern that shortages of IG may rise, potentially affecting medical treatment options.

Study Design And Methods: An international survey was developed to study how intravenous immunoglobulins (IVIGs) are used and managed within hospitals in case of shortages.

View Article and Find Full Text PDF

The emergence of SARS-CoV-2 Omicron variant has led to a complete reconfiguration of the therapeutic landscape, with all monoclonal antibodies having lost any neutralization activity. We report here a case series of 75 immunocompromised patients infected by the Omicron variant who benefited from COVID-19 convalescent plasma (CCP). At Day 28, the overall survival was 76% (95% CI 67-86) with no significant difference in the clinical outcome between patients with hematological malignancies, solid organ transplantation or autoimmune diseases.

View Article and Find Full Text PDF

BACKGROUNDWeakly virulent environmental mycobacteria (EM) can cause severe disease in HLA-DRB1*15:02 or 16:02 adults harboring neutralizing anti-IFN-γ autoantibodies (nAIGAs). The overall prevalence of nAIGAs in the general population is unknown, as are the penetrance of nAIGAs in HLA-DRB1*15:02 or 16:02 individuals and the proportion of patients with unexplained, adult-onset EM infections carrying nAIGAs.METHODSThis study analyzed the detection and neutralization of anti-IFN-γ autoantibodies (auto-Abs) from 8,430 healthy individuals of the general population, 257 HLA-DRB1*15:02 or 16:02 carriers, 1,063 patients with autoimmune disease, and 497 patients with unexplained severe disease due to EM.

View Article and Find Full Text PDF
Article Synopsis
  • Several high-income countries have ended the practice of deferring gay, bisexual, and other men who have sex with men (MSM) from donating blood, moving towards a gender-neutral donor selection approach.
  • An international symposium held in April 2023 brought together experts to discuss the impacts of this shift on transfusion safety and the challenges of implementing such policies.
  • Findings indicate that most countries adopted similar strategies for this transition, which were positively received by stakeholders and showed reassuring safety data, although further research on HIV risks is needed.
View Article and Find Full Text PDF

Background And Objectives: Pathogen reduction (PR) technology may reduce the risk of transfusion-transmitted infections (TTIs), notably transfusion-transmitted bacterial infection (TTBI) associated with platelet concentrates (PCs). PR (amotosalen/UVA treatment) was implemented for all PCs transfused in France in November 2017. No bacterial detection was in place beforehand.

View Article and Find Full Text PDF
Article Synopsis
  • The CORIPLASM trial aimed to assess whether covid-19 convalescent plasma is effective in treating hospitalized adults with moderate covid-19, including those with weakened immune systems.
  • Conducted across 19 hospitals in France, the trial included 120 participants randomly assigned to receive either convalescent plasma or usual care between April 2020 and April 2021.
  • Key outcomes measured included the proportion of patients experiencing worsening symptoms by day 4 and survival without needing assisted ventilation by day 14, while secondary outcomes assessed overall survival and recovery times.
View Article and Find Full Text PDF

Background And Objectives: As part of a large-scale project to safely increase plasma collection in Europe, the current scoping review identifies the existing evidence (gaps) on adverse events (AEs) and other health effects in plasmapheresis donors, as well as factors that may be associated with such events/effects.

Materials And Methods: We searched six databases and three registries. Study characteristics (publication type, language, study design, population, outcomes, associated factors, time of assessment, duration of follow-up, number and frequency of donations, convalescent plasma [y/n], setting and location) were synthesized narratively and in an interactive evidence gap map (EGM).

View Article and Find Full Text PDF

Importance: Red blood cell transfusion (RBCT) is frequently required in the early post-kidney transplant period, but long-term outcomes associated with RBCT is controversial. Therefore, it may be relevant to investigate the association between RBCT characteristics and transplant outcomes.

Objective: To study the association between RBC storage duration and transplant outcomes.

View Article and Find Full Text PDF

Background And Objectives: Data from 21 years (2000-2020) of haemovigilance were used to assess human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) incidence rates in repeat blood donors and the occurrence of transfusion-transmitted (TT) viral infections.

Materials And Methods: Blood donors who converted for HIV, HCV or HBV markers within serial three-year analysis periods were included. Epidemiological and virological data were retrieved from the national epidemiological donor database and were supplemented with information on blood components and the infection status of recipients of the previous negative donation (D.

View Article and Find Full Text PDF

At the symposium organized by the International Plasma and Fractionation Association and European Blood Alliance, experts presented their views and experiences showing that the public sector and its blood establishments may strengthen the collection and increase the supply of plasma using the right strategies in plasma donor recruitment, retention and protection, scaling-up collection by increasing the number of donors within improved/new infrastructure, supportive funding, policies and legislation as well as harmonization of clinical guidelines and the collaboration of all stakeholders. Such approaches should contribute to increased plasma collection in Europe to meet patients' needs for plasma-derived medicinal products, notably immunoglobulins and avoid shortages. Overall, presentations and discussions confirmed that European non-profit transfusion institutions are committed to increasing the collection of plasma for fractionation from unpaid donors through dedicated programmes as well as novel strategies and research.

View Article and Find Full Text PDF

Background And Objectives: There is a need for conversion of SARS-CoV-2 serology data from different laboratories to a harmonized international unit. We aimed to compare the performance of multiple SARS-CoV-2 antibody serology assays among 25 laboratories across 12 European countries.

Materials And Methods: To investigate this we have distributed to all participating laboratories a panel of 15 SARS-CoV-2 plasma samples and a single batch of pooled plasma calibrated to the WHO IS 20/136 standard.

View Article and Find Full Text PDF